PLAN FOR PATIENT INPUT TO SSRI REVIEW - strange they only mention Seroxat, what about the other brands ?

PLAN FOR PATIENT INPUT TO SSRI REVIEW



extract from - http://www.mhra.gov.uk/home/groups/pl-p/documents/committeedocument/con003485.pdf

MINUTES OF THE MEETING HELD ON FRIDAY 20 JUNE 2003 AT 1PM IN CONFERENCE ROOM (1) AT MARKET TOWERS


10.1 The Group was informed that the establishment of the CSM Expert Working Group on the safety of SSRIs and the recent action to contraindicate the use of paroxetine in children and adolescents had stimulated considerable media attention. A number of letters and emails had been received from patients or relatives/friends of patients about the safety of SSRIs, particularly paroxetine. Many of these individuals had expressed a desire to contribute to the work of the Group and in some cases had already provided details of their experiences. The amount of information describing patient experiences that had been included in these letters and emails varies considerably.

10.2 The Group endorsed MHRA’s proposal to ask each patient/relative to fill in a questionnaire. A copy of this questionnaire was provided to members of the Group who were asked to provide written comments on the proposed questionnaire to the secretariat by close of business Wednesday 25 June 2003.
10.3 The Group was informed that the Seroxat Users Group, which is a UK patient support group, has been in correspondence with the MHRA and its predecessor the Medicines Control Agency expressing its concerns about the safety of paroxetine. The MHRA had informed the Seroxat Users Group of its willingness to consider any reports of suspected adverse drug reactions submitted by members of the Seroxat User Group. In recent correspondence the Seroxat Users Group has expressed an interest in meeting with the Expert Group in order to contribute to its work.
10.4 The Expert Group commented that the views of the Seroxat User Group would provide a valuable contribution to the ongoing review. It was agreed that the Seroxat
Users Group should be given the opportunity to make a presentation to the Group should they wish. However, they might prefer a less formal meeting between representatives of the Expert Group and members of the MHRA to discuss their concerns. It was agreed that it would be helpful if the Seroxat Users Group provided a written representation which could then be considered by the Group.